Results for tag: "Non Insulin Diabetes Therapeutics"

The Non-Insulin Diabetes Therapeutics market is a subset of the broader Endocrine and Metabolic Disorders Drugs market, focusing specifically on treatments for diabetes that do not involve insulin. This market includes a variety of medications and therapeutic approaches designed to manage blood sugar levels and address the challenges posed by type 2 diabetes. Oral hypoglycemic agents, like metformin, sulfonylureas, thiazolidinediones, and DPP-4 inhibitors, are classic examples of non-insulin drugs. Moreover, recent advancements have led to the introduction of SGLT2 inhibitors and GLP-1 receptor agonists, both offering unique mechanisms of action and benefits. These treatments concentrate on improving insulin sensitivity, increasing insulin secretion, reducing glucose absorption in the gastrointestinal tract, and enhancing glucose excretion through the kidneys. Additionally, non-insulin diabetes therapeutics may include lifestyle management programs and adjunctive treatments for complications associated with diabetes, such as cardiovascular disease and neuropathy. As the prevalence of diabetes continues to rise, the development of new non-insulin medications and therapies remains an active area of pharmaceutical research and commercial competition, with many companies striving to improve glycemic control and reduce side effects associated with existing treatments. Some notable companies operating in the Non-Insulin Diabetes Therapeutics market include Merck & Co., AstraZeneca, Novo Nordisk, Eli Lilly and Company, Sanofi, Johnson & Johnson, Boehringer Ingelheim, and Takeda Pharmaceutical Company Show Less Read more